Family and Caregiver Schizophrenia Discussion Forum

Long-acting injectable antipsychotics update: lengthening the dosing interval


#1

Long-acting injectable (LAI) antipsychotics are a useful but underutilized option in the management of schizophrenia. Areas covered: This is a narrative review of newer LAI antipsychotics approved by the US Food and Drug Administration and is an update to a previously published review from 2013.

Intervals between injections can be longer than one month (six-week or two-month aripiprazole lauroxil, and three-month paliperidone palmitate). After a review of the evidence-base, guidance is offered on the appropriate selection among the LAI formulations of both first and second-generation antipsychotics.

Read the full paper here (Free PDF download):

http://sci-hub.cc/10.1080/14737175.2017.1371014